Stock Traders Buy Large Volume of ImmunityBio Call Options (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX) was the target of unusually large options trading activity on Thursday. Investors bought 8,015 call options on the company. This represents an increase of 36% compared to the average daily volume of 5,894 call options.

ImmunityBio Trading Up 18.2 %

Shares of IBRX stock traded up $0.43 during trading hours on Thursday, reaching $2.82. 13,090,030 shares of the company’s stock were exchanged, compared to its average volume of 5,655,877. ImmunityBio has a 1 year low of $2.28 and a 1 year high of $10.53. The stock has a market cap of $1.97 billion, a PE ratio of -3.05 and a beta of 0.86. The stock’s fifty day moving average price is $3.78 and its two-hundred day moving average price is $4.26.

Institutional Trading of ImmunityBio

Large investors have recently bought and sold shares of the stock. Captrust Financial Advisors purchased a new position in shares of ImmunityBio in the third quarter worth $41,000. Virtu Financial LLC acquired a new position in shares of ImmunityBio in the 3rd quarter valued at $51,000. Algert Global LLC purchased a new position in ImmunityBio in the 2nd quarter worth $86,000. Mirae Asset Global Investments Co. Ltd. lifted its position in ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after acquiring an additional 4,545 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new stake in ImmunityBio during the 2nd quarter valued at about $105,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Wall Street Analyst Weigh In

IBRX has been the topic of a number of recent analyst reports. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd. D. Boral Capital restated a “buy” rating and issued a $30.00 target price on shares of ImmunityBio in a research note on Thursday. Finally, BTIG Research assumed coverage on shares of ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price target on the stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.